Nick Reiner suffered a “complete break from reality” when doctors changed his psychiatric meds just before police say he ...

FDA grants Priority Review to AXS-05 (dextromethorphan/bupropion) for the treatment of agitation associated with Alzheimer disease.

Radial reports that teen depression is prevalent yet under-treated. Effective options include therapy, antidepressants, and ...

"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

Nick Reiner is reportedly no longer on suicide watch ahead of his arraignment Wednesday for the murders of his parents, Rob ...

Nick Reiner is reportedly no longer on suicide watch ahead of his arraignment in connection with the murder of his parents, ...

US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...

Managed care organization and providers should conduct early formulary reviews and education to ensure rapid access to dextromethorphan-bupropion upon approval, potentially delaying facility placement ...

Managed care organizations should evolve cost models to capture savings from dextromethorphan-bupropion’s safety profile, which avoids costly complications associated with traditional Alzheimer ...

Florida history important as Loxahatchee Battlefield Preservationists prepare to honor 188th anniversary of battle with ...

Only 12% report having access to a dedicated tobacco treatment team, counselor, or program to counsel patients on quitting.

While the FDA has yet to issue a warning for NAION, it is actively monitoring reports of the condition linked to GLP-1 drugs.